findmyKOL

Mark Meyer, MD

Basic profile

Cardiovascular Disease

ORCIDNone on fileNPI
RegionNew York, NY · NortheastSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationNot yet indexedOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Mark Meyer is a Cardiology physician.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →

Clinical & industry

trials, payments and federal funding
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

635 Madison Ave Ste 1401
New York, NY 100221009

Telephone

212-583-2999

Provider last certified this registry record 2 Jan 2020.

View the NPPES registry record

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    82.6%
    Statin19.8%
    Rosuvastatin Calcium57%Atorvastatin Calcium38%Simvastatin5%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)15%
    Valsartan45%Olmesartan Medoxomil28%Losartan Potassium17%Irbesartan5%Losartan-Hydrochlorothiazide5%
    Part D<11 patients

    + 17 more classes in this area

  • Metabolism & gastrointestinal

    9.3%
    SGLT2 inhibitor5.1%
    Jardiance100%
    Part D22 patients
    Biguanide (metformin)2.2%
    Metformin Hcl100%
    Part D13 patients

    + 2 more classes in this area

  • Blood & clotting

    7.5%
    Factor Xa inhibitor6%
    Eliquis100%
    Part D28 patients
    P2Y12 inhibitor1.5%
    Clopidogrel100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”